1. Home
  2. PRAX vs AXTA Comparison

PRAX vs AXTA Comparison

Compare PRAX & AXTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$304.80

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo Axalta Coating Systems Ltd.

AXTA

Axalta Coating Systems Ltd.

HOLD

Current Price

$28.11

Market Cap

5.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
AXTA
Founded
2015
1910
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Paints/Coatings
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
5.9B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
PRAX
AXTA
Price
$304.80
$28.11
Analyst Decision
Strong Buy
Buy
Analyst Count
15
14
Target Price
$572.13
$35.92
AVG Volume (30 Days)
306.4K
2.4M
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.74
Revenue
N/A
$5,117,000,000.00
Revenue This Year
N/A
$3.56
Revenue Next Year
$6,395.88
$2.93
P/E Ratio
N/A
$16.10
Revenue Growth
N/A
N/A
52 Week Low
$26.70
$26.28
52 Week High
$354.87
$35.72

Technical Indicators

Market Signals
Indicator
PRAX
AXTA
Relative Strength Index (RSI) 44.70 25.03
Support Level $290.36 $27.43
Resistance Level $322.32 $29.47
Average True Range (ATR) 16.80 0.92
MACD -3.69 -0.42
Stochastic Oscillator 25.12 10.82

Price Performance

Historical Comparison
PRAX
AXTA

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About AXTA Axalta Coating Systems Ltd.

Axalta Coating Systems Ltd is a manufacturer, marketer, and distributor of high-performance coatings systems. It operates in two segments: Performance Coatings and Mobility Coatings. The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial, and the Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The majority of its revenue is generated from the Mobility Coatings segment. Geographically, the company generates maximum revenue from the Europe, Middle East and Africa (EMEA) region, followed by North America, Asia Pacific, and Latin America.

Share on Social Networks: